# GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

Source: https://onco.cc/trials/nct04864054/  
OnCo record `nct04864054` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ECT204 T cells in hepatocellular carcinoma, run by Eureka Therapeutics Inc., now recruiting.

## Summary

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC is a phase 1/2 interventional study registered as NCT04864054 by Eureka Therapeutics Inc., with 60 participants planned, started 2022-03-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: ECT204 T cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04864054
- Phase: 1/2
- Setting: An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)
- Sponsor: Eureka Therapeutics Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04864054: https://clinicaltrials.gov/study/NCT04864054

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)

---
JSON: https://onco.cc/api/v1/entities/nct04864054.json